Acalabrutinib (ACP-196), also known as ACP-196, is an orally available inhibitor of Brutons tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies, it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.
Molecular Weight:
465.51
Purity:
98.94%
CAS Number:
[1420477-60-6]
Formula:
C26H23N7O2
Target:
BTK
T3626
* VAT and and shipping costs not included. Errors and price changes excepted
